Little Green Pharma completes Cannatrek merger, builds global cannabis player
What's the deal? Little Green PharmaDealroom has a profile for this one. Try Dealroom → (ASX:LGP) has completed its merger with CannatrekDealroom has a profile for this one. Try Dealroom →, forming what the combined group calls one of the largest pure-play medicinal cannabis companies globally. The deal joins Cannatrek's Australian cultivation and manufacturing with Little Green Pharma's European production and distribution base. Terms were not disclosed.
What's the endgame? The combined business, branded the LGP Cannatrek Group, pairs Cannatrek's AU-GMP certified manufacturing and domestic brands with a European platform anchored by a Danish cultivation site the company calls the largest of its kind in Europe. From there, the group supplies Germany, France, and the UK.
The rationale leans on complementary strengths. Little Green Pharma says it will use Cannatrek's balance sheet and cash-generative Australian operations to scale Europe, while vertical integration across cultivation, manufacturing, distribution, clinics, and digital health is expected to lift margins.
Why now? The group is several months into integration, and its latest investor update lays out a staged plan. A "Foundation" stage focuses on operational integration and cost synergies; a "Build" stage, tied to year-end, targets a first phase of Danish expansion and initial sales of a registered product in France.
The new hire: Shareholders passed all resolutions at the annual general meeting, and a new group chief financial officer has started — a signal that integration has moved into execution. The appointment supports the finance function as the company pursues the later "Scale" stage, which aims to bring the Danish facility to full capacity and expand in North America, Germany, and the UK.
What could go wrong? The Australian market now faces tighter scrutiny of prescribing, advertising, and product quality. Germany bears watching too, where proposed amendments to its medical cannabis law include limits on telemedicine prescribing.
The signal: The group has named Australia, the UK, and Germany as core markets — the UK high-growth, Germany expanding rapidly after reclassification. Spreading across both established domestic and European demand positions the combined company differently from producers dependent on a single market.
Read more: kalkinemedia.com
